E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
giant cell arteritis |
reuscelarteriitis |
|
E.1.1.1 | Medical condition in easily understood language |
giant cell arteritis |
reuscelarteriitis |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objective: to evaluate arterial [18F]fluor-PEG-folate uptake on PET/CT in patients with active, large vessel GCA; and in the same patients after 9 months of standard treatment. |
Primaire doel: evalueren van arteriële [18F]fluor-PEG-folaat opname op de PET/CT in patiënten met actieve, grote vaten reuscelarteriitis ten tijde van de diagnose en na 9 maanden van reguliere behandeling. |
|
E.2.2 | Secondary objectives of the trial |
- Assessment of the relationship between the [18F]fluor-PEG-folate uptake after 9 months of treatment and clinical disease activity at that time point.
- Assessment of the relationship between the [18F]fluor-PEG-folate uptake after 9 months of treatment and the development of relapses during the first 9 months of treatment.
|
- Beoordelen van de relatie tussen [18F]fluor-PEG-folaat opname na 9 maanden behandeling en de ziekteactiviteit op dat tijdstip.
- Beoordelen van de relatie tussen [18F]fluor-PEG-folaat opname na 9 maanden behandeling en het ontwikkelen van ziekteopvlammingen gedurende de eerste 9 maanden van behandeling. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age ≥ 50 years at time of disease onset - Erythrocyte sedimentation rate (ESR) ≥50 mm/hr or C-reactive protein (CRP) ≥ 10 mg/L - Clinical symptoms of large vessel GCA (at least one of the following) at time of inclusion: constitutional symptoms (fatigue, fever, weight loss, and/or night sweats), limb claudication, or symptoms of polymyalgia rheumatica (i.e. shoulder and/or hip girdle pain associated with morning stiffness). - Imaging findings consistent with large vessel GCA at the time of inclusion (e.g. ultrasound, FDG-PET/CT) - Patients must be able to adhere to the study appointments and other protocol requirements. - Patients must be capable of giving informed consent and the consent must have been obtained prior to the study related procedures. |
- Leeftijd ≥ 50 jaar ten tijde van ontstaan van ziekte - Bloedbezinking (BSE) ≥50 mm/uur of C-reactive protein (CRP) ≥ 10 mg/L - Klinische symptomen suggestief voor grote vaten reuscelarteriitis (minstens een van volgende): constitutionele symptomen (moeheid, koorts, gewichtsverlies, en/of nachtzweten), claudication van ledematen, symptomen van polymyalgia rheumatica (d.w.z. schouder- en/of heupgordelpijn met ochtendstijfheid) - Bewijs voor reuscelarteriitis bij beeldvormend onderzoek (bijv. echografie, FDG-PET/CT) - Patiënten moeten in staat zijn zich te houden aan de studie afspraken en andere protocol verplichtingen. - Patiënten moeten in staat zijn om een geïnformeerde keuze te maken over deelname aan het onderzoek, en moeten toestemming geven voor start van het onderzoek. |
|
E.4 | Principal exclusion criteria |
- Clinical symptoms suggestive of cranial GCA (at least one of the following): new-onset localized headache, scalp tenderness, temporal artery abnormality (thickening, tenderness, and/or decreased pulsation), ischemia-related vision loss, stroke, transients ischemic attack, jaw or tongue claudication (pain upon mastication). - Ultrasound findings consistent with cranial GCA (e.g. halo sign in temporal or facial artery). - A prior positive temporal artery biopsy. - Initiation or dose escalation of systemic glucocorticoid therapy (oral, IM, IV) in the 4 weeks prior to inclusion - Initiation or dose escalation of disease-modifying antirheumatic drugs (DMARDs) within 3 months prior to inclusion - Treatment with any investigational drug within 3 months prior to inclusion. - Females with child bearing potential. Post-menopausal women with >12 months of amenorrhoea are considered to have no child bearing potential. Given the age distribution of patients with GCA, exclusion of females with child bearing potential will not lead to recruitment bias in the study. - Research-related radiation exposure (cumulative ≥5 mSv) in the year before inclusion.
|
- Klinische symptomen suggestief voor craniële reuscelarteriitis (minstens één van de volgende): nieuwe gelokaliseerde hoofdpijn, gevoelige hoofdhuid, afwijkende arteria temporalis bij lichamelijk onderzoek (verdikt, pijnlijk, verminderd pulserend), ischemisch visusverlies, CVA, TIA, kaak -of tongclaudicatio. - Echografische bevindingen suggestief voor craniële reuscelarteriitis (bijv. halo sign in arteria temporalis of facialis). - Een eerder positief biopt voor reuscelarteriitis. - Start dan wel dosisverhoging van systemisch werkzame glucocorticoiden (oraal, IM, IV) in 4 weken voorgaand aan inclusie - Start dan wel dosisverhoging van 'disease-modifying antirheumatic drugs' (DMARDs) in 3 maanden voorgaand aan inclusie - Behandeling met een ‘investigational drug’ in de 3 maanden voorgaand aan inclusie. - Vrouwen die vruchtbaar zijn. Postmenopauzale vrouwen met > 12 maanden amenorroe worden beschouwd als onvruchtbaar. - Onderzoeksgerelateerde blootstelling aan straling (cumulatief ≥5 mSv) in het jaar voorgaand aan inclusie.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Arterial [18F]fluor-PEG-folate uptake on PET/CT in patients with active, large vessel GCA; and in the same patients after 9 months of standard treatment. |
Arteriële [18F]fluor-PEG-folaat opname op de PET/CT in patiënten met actieve, grote vaten reuscelarteriitis; en in dezelfde patiënten na 9 maanden van reguliere behandeling. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
-The relationship between the [18F]fluor-PEG-folate uptake after 9 months of treatment and clinical disease activity at that time point.
-The relationship between the [18F]fluor-PEG-folate uptake after 9 months of treatment and the development of relapses during the first 9 months of treatment. |
-De relatie tussen [18F]fluor-PEG-folaat opname na 9 maanden behandeling en de ziekteactiviteit op dat tijdstip.
-De relatie tussen [18F]fluor-PEG-folaat opname na 9 maanden behandeling en het ontwikkelen van ziekteopvlammingen gedurende de eerste 9 maanden van behandeling. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS. |
Laatste visite van laatste proefpersoon. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |